Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Phosphorus containing other than solely as part of an...
Reexamination Certificate
2007-02-06
2007-02-06
Lukton, David (Department: 1654)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Phosphorus containing other than solely as part of an...
C514S007600, C514S043000, C514S049000, C514S075000, C514S119000
Reexamination Certificate
active
11053024
ABSTRACT:
Novel phosphoramidate derivatives of hydroxy functional or amino functional compounds, including amino acids, peptides, peptidomimetics and nucleotide analogs, are described. The compounds enable enhanced intracellular delivery of drugs as their corresponding phosphate esters or amides. Described phosphoramidate compounds exhibit antiproliferative activity. Pharmaceutical formulations are provided for treatment of cancers.
REFERENCES:
patent: 5233031 (1993-08-01), Borch et al.
patent: 5472956 (1995-12-01), Borch et al.
patent: WO 93 06120 (1993-04-01), None
Chen et al., “The synthesis of O-monosaccharideyl-methoxycarbonyl-phosphonamidates by Arbuzov reaction”,Chinese Chemical Letters, vol. 6, No. 1, 1995, pp. 23-26.
Siddiqui et al., “Design and synthesis of lipophilic phosphoramidate D4T-MP prodrugs expressing high potency against HIV in cell culture: Structural determinants for in vitro activity and qsar”,Journal of Medical Chemistry, vol. 42, No. 20, 1999, pp. 4122-4128.
McGuigan et al., “Phosphoramidates as potent prodrugs of anti-HIV nucleotides: Studies in the amino region”,Antiviral Chemistry and Chemotherapy, vol. 7, No. 1, 1996, pp. 31-36.
Meyers et al., “Design and synthesis of novel nucleotide prodrugs”, American Association for Cancer Research, 2000, Abstract No. 100710.
Kolibaba et al., “Protein tryosine kinases and cancer”,Biochim. Biophys. Acta, vol. 1333, 1997, pp. F217-F248.
Van der Geer et al., “Receptor protein-tyrosine kinases and their signal transduction pathways”,Ann. Rev. Cell. Bio., vol. 10, 1994, pp. 251-337.
Moran et al., “Src homology 2 domains direct protein-protein interactions in signal transduction”,PNAS, USA, vol. 87, 1990, pp. 8622-8626.
Anderson et al., “Binding of SH2 domains of phospholipase C gamma 1, GAP and Src to activated growth factor receptors”,Science, vol. 250, 1990, pp. 979-982.
Cantley et al., “Oncogenes and signal transduction”,Cell, vol. 64, 1991, pp. 281-302.
Songyang et al., “Recognition and specificity in protein tryosine kinase-mediated signalling”,TIBS, vol. 20, 1995, pp. 470-475.
Saltiel et al., “Targeting signal transduction in the discovery of antiproliferative drugs”,Chem. and Biol., vol. 3, 1996, pp. 887-893.
Gilmer et al., “Peptide inhibitors of Src SH3-SH2 phosphoprotein interactions”,J. Biol. Chem., vol. 269, 1994, pp. 31711-31719.
Lunney et al., “Structure-based design of a novel series of nonpeptide ligands that bind to the pp60srcSH2—domain”,J. Am. Chem. Soc., vol. 119, 1997, pp. 12471-12476.
Plummer et al., “Design, synthesis and cocrystal structure of a nonpeptide Src SH2 domain ligand”,J. Med. Chem., vol. 40, 1997, pp. 3719-3725.
Domchek et al., “Inhibition of SH2 domain/phosphoprotein association by a nonhydrolyzable phosphonopeptide”,Biochemistry, vol. 31, 1992, pp. 9865-9870.
Burke et al., “Nonhydrolyzable phosphotyrosyl mimetics for the preparation of phosphatase-resistant SH2 domain inhibitors”,Biochemistry, vol. 33, 1994, pp. 6490-6494.
Ye et al., “L-O-(2-malonyl)tyrosine: A new phosphotyrosyl mimetic for the preparation of Src homology 2 domain inhibitory peptides”,J. Med. Chem., vol. 38, 1995, pp. 4270-4275.
Burke et al., “Conformationally constrained phosphotyrosyl mimetics designed as monomeric Src homology 2 domain inhibitors”,J. Med. Chem., vol. 38, 1995, pp. 1386-1396.
Burke et al., “4′-O-[2-(2-fluoromalonyl)]-L-tyrosine: A phosphotyrosyl mimic for the preparation of signal transduction inhibitory peptides”,J. Med. Chem, vol. 39, 1996, pp. 1021-1027.
Llinas-Brunet et al., “Phosphotyrosine-containing dipeptides as high-affinity ligands for the p56 lck SH2 domain”,J. Med. Chem., vol. 42, 1999, pp. 722-729.
Lee et al., “Acquisition of high-affinity, SH2-targeted ligands via a spatially focused library”,J.Med. Chem, vol. 42, 1999, pp. 784-787.
Beaulieu et al., “Ligands for the tyrosine kinase p56lck SH2 domain: Discovery of potent dipeptide derivatives with monocharged, nonhydrolyzable phosphate replacements”,J. Med. Chem., vol. 42, 1999, pp. 1757-1766.
Fries et al., Synthesis and biological evaluation of 5-fluoro-2′-deoxyuridine phosphoamidate analogs,J. Med. Chem., vol. 38, 1995, pp. 2672-2680.
Meyers et al., “Synthesis and Biological Activity of Novel 5-Fluro-2′-deoxyuridine Phosphoramidate Prodrugs,” Journal of Medicinal Chemistry, vol. 43, No. 22, 2000, pp. 4313-4318.
Borch et al., “Synthesis and Evaluation of Nitroheterocyclic Phorphoramidates as Hypoxia-Selective Alkylating Agents,” Journal of Medicinal Chemistry, vol. 43, No. 11, 2000, pp. 2258-2265.
Borch Richard F.
Garrido-Hernandez Hugo
Tobias Sandra C.
Barnes & Thornburg LLP
Lukton David
Purdue Research Foundation
LandOfFree
Phosphoramidates and methods therefor does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Phosphoramidates and methods therefor, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Phosphoramidates and methods therefor will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3852464